Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201
Excerpt from the Press Release:
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, will deliver a poster presentation at The Liver Meeting® (November 4-8, 2022), hosted by the American Association for the Study of Liver Diseases (AASLD). The poster highlights clinical data for its small molecule capsid assembly modulator-empty capsid (CAM-E) drug candidate, ALG-000184, which is in development for the treatment of chronic hepatitis B (CHB). The poster includes the following key results from the ongoing Phase 1 study ALG-000184-201 (NCT04536337) in HBeAg-positive CHB cohorts that received 28 daily oral doses of ALG-000184 at either the 100 mg or 300 mg dose levels:
- ALG-000184 reduced hepatitis B surface antigen (HBsAg) levels in a subset of HBeAg-positive subjects
- Among 7 subjects with evaluable HBsAg data who were treated with 300 mg ALG-000184, 3 subjects experienced reductions in HBsAg levels of 0.2-0.8 log10 IU/mL
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?